Skip to main content
GutCited

Galactooligosaccharides (GOS) pour Irritable Bowel Syndrome (IBS)

B Preuves Au moins un essai randomisé le soutient, avec des résultats globalement concordants.

Reduces IBS symptoms (pain, bloating, flatulence) in dose-dependent manner. 3.5 g/day showed better results than 7 g/day (excess fermentation at higher dose).

<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dgalactooligosaccharides\u0026condition\u003Dibs'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

B

En conclusion

Reduces IBS symptoms (pain, bloating, flatulence) in dose-dependent manner. 3.5 g/day showed better results than 7 g/day (excess fermentation at higher dose).

Key Study Findings

Review
Interplay of probiotics, prebiotics, synbiotics and postbiotics: a review of their therapeutic potential for gastrointestinal …
Dose: None vs: None Outcome: None Effet: None None

Population: review of prebiotics, probiotics, synbiotics, postbiotics for gastrointestinal inflammation

Randomized Controlled Trial n=45 12 weeks Double-blind
All FODMAPs Aren't Created Equal: Results of a Randomized Reintroduction Trial in Patients With Irritable …
Dose: None vs: Sequential FODMAP subgroup reintroduction Outcome: Abdominal pain and bloating severity Effet: None p=0.007 fructans; p=0.04 GOS

Population: IBS patients (Rome IV) who improved on FODMAP diet

Randomized Controlled Trial 4 weeks Double-blind
Is a Simplified, Less Restrictive Low FODMAP Diet Possible? Results From a Double-Blind, Pilot Randomized …
Dose: None vs: Traditional low FODMAP diet Outcome: IBS symptom response Effet: None None

Population: IBS-D patients (Rome IV)

Systematic Review
Nutritional Interventions in Adult Patients With Irritable Bowel Syndrome: An Umbrella Review of Systematic Reviews …
Dose: None vs: Various Outcome: IBS symptom improvement Effet: Probiotics abdominal pain RR 4.04 (2.36-6.92) None

Population: Adult IBS patients

Randomized Controlled Trial n=34 8 weeks Single-blind
A randomized trial of inulin for bowel symptoms, depression and quality of life in constipation …
Dose: 9.2 g/day total (4.6 g twice daily) vs: Maltodextrin 9.2 g/day placebo Outcome: IBS-SSS score and IBS-QoL score Effet: IBS-SSS: 267.3→195.8; IBS-QoL: 61.0→77.4 0.026 (IBS-SSS); 0.006 (QoL)

Population: Adults with constipation-predominant IBS

Other
Biotechnological Tools for the Production of Low-FODMAP Wholegrain Wheat and Rye Cookies and Crackers.
Dose: None vs: Standard wholegrain flour products Outcome: FODMAP content reduction in cookies and crackers Effet: Up to 99.5% FODMAP reduction (wheat malt) None

Population: Laboratory food science study (no human subjects)

Key Statistics

3

Études

400

Participants

↑

Positive

B

Note

Referenced Papers

Foods (Basel, Switzerland) 2025 3 citations
Archivos argentinos de … 2024 3 citations
Frontline gastroenterology 2021 56 citations
Critical reviews in … 2019 35 citations
Foods (Basel, Switzerland) 2019 21 citations
The American journal … 2019 15 citations
Journal of gastroenterology … 2017 181 citations
International journal of … 2017 146 citations
Journal of gastroenterology … 2017 32 citations
Current opinion in … 2017 24 citations
World journal of … 2016 238 citations
Scandinavian journal of … 2016 17 citations
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 2016 2 citations
Journal of neurogastroenterology … 2015 60 citations
Menopause international 2009 29 citations
Alimentary pharmacology & … 2006 629 citations
The British journal … 2001 166 citations

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Posologies couramment utilisées

general:
2.5-5 g/day
ibssupport:
3.5 g/day (optimal dose; higher doses may increase symptoms)
infantgutsupport:
0.24-0.48 g/100 mL formula (added to infant formula)

Limite supérieure : Well-tolerated up to 15 g/day; optimal dose appears to be 3.5-5 g/day

Posologies étudiées dans la recherche

Posologie Durée Effet N
None -- Positive --
None 12 weeks Negative 45
None 4 weeks Mixed --
None -- Positive --
9.2 g/day total (4.6 g twice daily) 8 weeks Positive 34
None -- Positive --
1e9 CFU/day + GOS 10 g/L -- Positive --
None -- Neutral --

Moment optimal de prise : With meals; start with lower dose and increase gradually

Safety & Side Effects

Effets indésirables signalés

  • ⚠ Gas and bloating (especially above 5 g/day; dose-response is U-shaped)
  • ⚠ Flatulence at higher doses
  • ⚠ Abdominal cramping if dose increased too quickly
  • ⚠ May worsen symptoms in FODMAP-sensitive individuals

Interactions connues

  • ● Other FODMAPs (cumulative fermentation in sensitive individuals)
  • ● Lactose-containing products (GOS is derived from lactose; generally safe for lactose-intolerant individuals as GOS itself is lactose-free)

Apport maximal tolérable : Well-tolerated up to 15 g/day; optimal dose appears to be 3.5-5 g/day

Consultez toujours votre professionnel de santé avant de commencer tout complément alimentaire.Consultez toujours votre professionnel de santé avant de commencer tout complément alimentaire.

Frequently Asked Questions

Does Galactooligosaccharides (GOS) help with Irritable Bowel Syndrome (IBS)?
Based on 3 studies with 400 participants, there is moderate evidence from clinical studies that Galactooligosaccharides (GOS) may support Irritable Bowel Syndrome (IBS) management. Our evidence grade is B (Good Evidence).
How much Galactooligosaccharides (GOS) should I take for Irritable Bowel Syndrome (IBS)?
Studies have used various dosages. A commonly studied range is 2.5-5 g/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Galactooligosaccharides (GOS)?
Reported side effects may include Gas and bloating (especially above 5 g/day; dose-response is U-shaped), Flatulence at higher doses, Abdominal cramping if dose increased too quickly, May worsen symptoms in FODMAP-sensitive individuals. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Galactooligosaccharides (GOS) and Irritable Bowel Syndrome (IBS)?
We rate the evidence as Grade B (Good Evidence). This rating is based on 3 peer-reviewed studies with 400 total participants. The overall direction of effect is positive.

References

  1. [1] Radhika Baheti et al.. Food Res Int. 2026. Interplay of probiotics, prebiotics, synbiotics and postbiotics: a review of their therapeutic potential for gastrointestinal inflammation. doi:10.1016/j.foodres.2026.118598 PubMed
  2. [2] Prashant Singh et al.. Clin Gastroenterol Hepatol. 2025. Is a Simplified, Less Restrictive Low FODMAP Diet Possible? Results From a Double-Blind, Pilot Randomized Controlled Trial. doi:10.1016/j.cgh.2024.04.021 PubMed
  3. [3] Shanti Eswaran et al.. Clin Gastroenterol Hepatol. 2025. All FODMAPs Aren't Created Equal: Results of a Randomized Reintroduction Trial in Patients With Irritable Bowel Syndrome. doi:10.1016/j.cgh.2024.03.047 PubMed
  4. [4] Sheida Zeraattalab-Motlagh et al.. Nutr Rev. 2025. Nutritional Interventions in Adult Patients With Irritable Bowel Syndrome: An Umbrella Review of Systematic Reviews and Meta-analyses of Randomized Clinical … doi:10.1093/nutrit/nuae107 PubMed
  5. [5] Qi Yao et al.. Nutrients. 2025. Lactobacillus plantarum and Galacto-Oligosaccharides Synbiotic Relieve Irritable Bowel Syndrome by Reshaping Gut Microbiota and Attenuating Mast Cell Hyperactivation. doi:10.3390/nu17101670 PubMed
  6. [6] Aleksandra M Torbica et al.. Foods. 2025. FODMAP Profile of Wholegrain Pasta. doi:10.3390/foods14040667 PubMed
  7. [7] Çağlar Akçalı et al.. Sci Rep. 2025. A randomized trial of inulin for bowel symptoms, depression and quality of life in constipation predominant IBS. doi:10.1038/s41598-025-16321-w PubMed
  8. [8] Aleksandra M Torbica et al.. Foods. 2025. Biotechnological Tools for the Production of Low-FODMAP Wholegrain Wheat and Rye Cookies and Crackers. doi:10.3390/foods14040582 PubMed
  9. [9] Yusuf Serhat Karakülah et al.. Int J Mol Sci. 2025. Clinical Applications of Bovine Colostrum in GastrointestinaI Disorders: Mechanisms, Evidence, and Therapeutic Potential. doi:10.3390/ijms262110673 PubMed
  10. [10] Line Graser Jensen et al.. Gastroenterol Res Pract. 2025. Modification of the Low FODMAP Diet Is Feasible in the Treatment of Irritable Bowel Syndrome: A Randomised Crossover Study. doi:10.1155/grp/4152978 PubMed
  11. [11] Wing-Yan Wong et al.. Food Funct. 2025. A non-pharmacological intervention for insomnia: tryptophan-fructooligosaccharides combination improves sleep in mice via anti-inflammation and gut microbiota modulation. doi:10.1039/d5fo01651g PubMed
  12. [12] Karen Van den Houte et al.. Gastroenterology. 2024. Efficacy and Findings of a Blinded Randomized Reintroduction Phase for the Low FODMAP Diet in Irritable Bowel Syndrome. doi:10.1053/j.gastro.2024.02.008 PubMed
  13. [13] Marcus Schmidt et al.. Crit Rev Food Sci Nutr. 2024. FODMAP reduction strategies for nutritionally valuable baking products: current state and future challenges. doi:10.1080/10408398.2023.2195026 PubMed
  14. [14] Anita Gąsiorowska et al.. J Clin Med. 2024. Efficacy and Safety of a Mixture of Microencapsulated Sodium Butyrate, Probiotics, and Short Chain Fructooligosaccharides in Patients with Irritable Bowel … doi:10.3390/jcm14010006 PubMed
  15. [15] María Del C Toca et al.. Arch Argent Pediatr. 2024. Postbiotics: A new member in the biotics family. doi:10.5546/aap.2023-10168.eng PubMed
  16. [16] Sarvesh V Surve et al.. J Appl Microbiol. 2024. Laboratory domestication of Lactiplantibacillus plantarum alters some phenotypic traits but causes non-novel genomic impact. doi:10.1093/jambio/lxae035 PubMed
  17. [17] Sean M Garvey et al.. Gastro Hep Adv. 2024. Safety and Tolerability of Microbial Inulinase Supplementation in Healthy Adults: A Randomized, Placebo-Controlled Trial. doi:10.1016/j.gastha.2024.05.013 PubMed
  18. [18] Justin L Guice et al.. Front Nutr. 2023. Microbial inulinase promotes fructan hydrolysis under simulated gastric conditions. doi:10.3389/fnut.2023.1129329 PubMed
  19. [19] Woori Na et al.. Nutr Res Pract. 2023. Food contributing to fermentable oligosaccharide, disaccharide, monosaccharide, and polyols intake in Korean adults. doi:10.4162/nrp.2023.17.6.1201 PubMed
  20. [20] V N Drozdov et al.. Vopr Pitan. 2023. [Clinical efficacy of a modern probiotic for the correction of intestinal microflora in patients with irritable bowel syndrome with diarrhea … doi:10.33029/0042-8833-2023-92-4-92-103 PubMed
  21. [21] Ashinshana U Illippangama et al.. Carbohydr Polym. 2022. Inulin as a functional ingredient and their applications in meat products. doi:10.1016/j.carbpol.2021.118706 PubMed
  22. [22] Andrew Thomas et al.. Am J Lifestyle Med. 2022. Dietary Modification for the Restoration of Gut Microbiome and Management of Symptoms in Irritable Bowel Syndrome. doi:10.1177/15598276211012968 PubMed
  23. [23] J B J Kamphuis et al.. FASEB J. 2022. Increased fermentable carbohydrate intake alters colonic mucus barrier function through glycation processes and increased mast cell counts. doi:10.1096/fj.202100494RRR PubMed
  24. [24] Anita Gąsiorowska et al.. J Clin Med. 2022. Effects of Microencapsulated Sodium Butyrate, Probiotics and Short Chain Fructooligosaccharides in Patients with Irritable Bowel Syndrome: A Study Protocol of … doi:10.3390/jcm11216587 PubMed
  25. [25] Uzma Mustafa et al.. Indian J Gastroenterol. 2022. The challenges of implementing low fermentable oligo-, di-, mono-saccharides and polyol diet in India: An analysis of available data. doi:10.1007/s12664-022-01250-7 PubMed
  26. [26] Susie Jung et al.. Nutrients. 2022. A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effects of Multi-Strain Synbiotic in Patients with Functional Diarrhea and High Fecal … doi:10.3390/nu14235017 PubMed
  27. [27] Diego Currò. Expert Rev Gastroenterol Hepatol. 2022. Current evidence on the therapeutic use of fiber in irritable bowel syndrome. doi:10.1080/17474124.2021.1924057 PubMed
  28. [28] Marcel Skejovic Joehnke et al.. Food Chem X. 2021. Nutritional and anti-nutritional properties of lentil (Lens culinaris) protein isolates prepared by pilot-scale processing. doi:10.1016/j.fochx.2020.100112 PubMed
  29. [29] Christopher J Black et al.. Frontline Gastroenterol. 2021. Best management of irritable bowel syndrome. doi:10.1136/flgastro-2019-101298 PubMed
  30. [30] Cristina Iribarren et al.. Nutrients. 2021. The Effects of Human Milk Oligosaccharides on Gut Microbiota, Metabolite Profiles and Host Mucosal Response in Patients with Irritable Bowel … doi:10.3390/nu13113836 PubMed
  31. [31] Johannes Pitsch et al.. Foods. 2021. FODMAP Fingerprinting of Bakery Products and Sourdoughs: Quantitative Assessment and Content Reduction through Fermentation. doi:10.3390/foods10040894 PubMed
  32. [32] Elodie Schneider et al.. J Nutr. 2021. FODMAP Consumption by Adults from the French Population-Based NutriNet-Santé Cohort. doi:10.1093/jn/nxab207 PubMed
  33. [33] Teodora Surdea-Blaga et al.. Curr Opin Gastroenterol. 2021. Dietary interventions and irritable bowel syndrome - what really works? doi:10.1097/MOG.0000000000000706 PubMed
  34. [34] Lena Böhn et al.. Neurogastroenterol Motil. 2021. A randomized double-blind placebo-controlled crossover pilot study: Acute effects of the enzyme α-galactosidase on gastrointestinal symptoms in irritable bowel syndrome … doi:10.1111/nmo.14094 PubMed
  35. [35] Selina R Cox et al.. Gastroenterology. 2020. Effects of Low FODMAP Diet on Symptoms, Fecal Microbiome, and Markers of Inflammation in Patients With Quiescent Inflammatory Bowel Disease … doi:10.1053/j.gastro.2019.09.024 PubMed
  36. [36] Barbara Skrzydło-Radomańska et al.. Nutrients. 2020. The Effectiveness of Synbiotic Preparation Containing Lactobacillus and Bifidobacterium Probiotic Strains and Short Chain Fructooligosaccharides in Patients with Diarrhea Predominant … doi:10.3390/nu12071999 PubMed
  37. [37] Bridgette Wilson et al.. Am J Gastroenterol. 2020. β-Galactooligosaccharide in Conjunction With Low FODMAP Diet Improves Irritable Bowel Syndrome Symptoms but Reduces Fecal Bifidobacteria. doi:10.14309/ajg.0000000000000641 PubMed
  38. [38] Karin Ried et al.. Nutr Res. 2020. Herbal formula improves upper and lower gastrointestinal symptoms and gut health in Australian adults with digestive disorders. doi:10.1016/j.nutres.2020.02.008 PubMed
  39. [39] Jasper B J Kamphuis et al.. Gastroenterology. 2020. Lactose and Fructo-oligosaccharides Increase Visceral Sensitivity in Mice via Glycation Processes, Increasing Mast Cell Density in Colonic Mucosa. doi:10.1053/j.gastro.2019.10.037 PubMed
  40. [40] Jitka Laurent et al.. Int J Food Microbiol. 2020. Variability in yeast invertase activity determines the extent of fructan hydrolysis during wheat dough fermentation and final FODMAP levels in … doi:10.1016/j.ijfoodmicro.2020.108648 PubMed
  41. [41] Khadijeh Abhari et al.. Eur J Nutr. 2020. Is Bacillus coagulans supplementation plus low FODMAP diet superior to low FODMAP diet in irritable bowel syndrome management? doi:10.1007/s00394-019-02060-y PubMed
  42. [42] Paul Moayyedi et al.. J Can Assoc Gastroenterol. 2019. Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Irritable Bowel Syndrome (IBS). doi:10.1093/jcag/gwy071 PubMed
  43. [43] Bridgette Wilson et al.. Am J Clin Nutr. 2019. Prebiotics in irritable bowel syndrome and other functional bowel disorders in adults: a systematic review and meta-analysis of randomized controlled … doi:10.1093/ajcn/nqy376 PubMed
  44. [44] Xiao Jing Wang et al.. Aliment Pharmacol Ther. 2019. Review article: biological mechanisms for symptom causation by individual FODMAP subgroups - the case for a more personalised approach to … doi:10.1111/apt.15419 PubMed
  45. [45] Praveena Thirunathan et al.. Crit Rev Food Sci Nutr. 2019. Processing methods for reducing alpha-galactosides in pulses. doi:10.1080/10408398.2018.1490886 PubMed
  46. [46] Ewa Pejcz et al.. Foods. 2019. Technological Methods for Reducing the Content of Fructan in Wheat Bread. doi:10.3390/foods8120663 PubMed
  47. [47] Afrin Kamal et al.. Am J Gastroenterol. 2019. Influence of Dietary Restriction on Irritable Bowel Syndrome. doi:10.1038/s41395-018-0241-2 PubMed
  48. [48] Megan Rossi et al.. Clin Gastroenterol Hepatol. 2018. Volatile Organic Compounds in Feces Associate With Response to Dietary Intervention in Patients With Irritable Bowel Syndrome. doi:10.1016/j.cgh.2017.09.055 PubMed
  49. [49] C J Tuck et al.. Am J Gastroenterol. 2018. Increasing Symptoms in Irritable Bowel Symptoms With Ingestion of Galacto-Oligosaccharides Are Mitigated by α-Galactosidase Treatment. doi:10.1038/ajg.2017.245 PubMed
  50. [50] Tobias Pöhnl et al.. J Agric Food Chem. 2018. Impact of Cultivation Method and Cultivar Selection on Soluble Carbohydrates and Pungent Principles in Onions ( Allium cepa L.). doi:10.1021/acs.jafc.8b05018 PubMed
  51. [51] Bridgette Wilson et al.. J Gastroenterol Hepatol. 2017. Prebiotic inulin-type fructans and galacto-oligosaccharides: definition, specificity, function, and application in gastrointestinal disorders. doi:10.1111/jgh.13700 PubMed
  52. [52] Jane Varney et al.. J Gastroenterol Hepatol. 2017. FODMAPs: food composition, defining cutoff values and international application. doi:10.1111/jgh.13698 PubMed
  53. [53] Magdy El-Salhy et al.. Int J Mol Med. 2017. Dietary fiber in irritable bowel syndrome (Review). doi:10.3892/ijmm.2017.3072 PubMed
  54. [54] F Azpiroz et al.. Neurogastroenterol Motil. 2017. Effects of scFOS on the composition of fecal microbiota and anxiety in patients with irritable bowel syndrome: a randomized, double … doi:10.1111/nmo.12911 PubMed
  55. [55] Selina R Cox et al.. J Crohns Colitis. 2017. Fermentable Carbohydrates [FODMAPs] Exacerbate Functional Gastrointestinal Symptoms in Patients With Inflammatory Bowel Disease: A Randomised, Double-blind, Placebo-controlled, Cross-over, Re-challenge Trial. doi:10.1093/ecco-jcc/jjx073 PubMed
  56. [56] Emma P Halmos. J Gastroenterol Hepatol. 2017. When the low FODMAP diet does not work. doi:10.1111/jgh.13701 PubMed
  57. [57] Eirini Dimidi et al.. Curr Opin Clin Nutr Metab Care. 2017. Irritable bowel syndrome and diet: where are we in 2018? doi:10.1097/MCO.0000000000000416 PubMed
  58. [58] Jennifer Erickson et al.. Nutr J. 2017. Gastrointestinal tolerance of low FODMAP oral nutrition supplements in healthy human subjects: a randomized controlled trial. doi:10.1186/s12937-017-0256-3 PubMed
  59. [59] H M Staudacher et al.. Aliment Pharmacol Ther. 2017. Editorial: metabolic adaptation of colonic microbiota to galactooligosaccharides - good news for prebiotics in irritable bowel syndrome? doi:10.1111/apt.13976 PubMed
  60. [60] Danuta Owczarek et al.. World J Gastroenterol. 2016. Diet and nutritional factors in inflammatory bowel diseases. doi:10.3748/wjg.v22.i3.895 PubMed
  61. [61] Markku Hillilä et al.. Scand J Gastroenterol. 2016. Does oral α-galactosidase relieve irritable bowel symptoms? doi:10.3109/00365521.2015.1063156 PubMed
  62. [62] Martin Raithel et al.. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2016. [Non-allergic gluten sensitivity. A controversial disease - or not yet sufficiently explored?]. doi:10.1007/s00103-016-2366-z PubMed
  63. [63] Marina Iacovou et al.. J Neurogastroenterol Motil. 2015. The Low FODMAP Diet and Its Application in East and Southeast Asia. doi:10.5056/jnm15111 PubMed
  64. [64] Heidi M Staudacher et al.. J Nutr. 2012. Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome. doi:10.3945/jn.112.159285 PubMed
  65. [65] Michael de Vrese. Menopause Int. 2009. Health benefits of probiotics and prebiotics in women. doi:10.1258/mi.2009.009008 PubMed
  66. [66] Angelo Andriulli et al.. J Clin Gastroenterol. 2008. Clinical trial on the efficacy of a new symbiotic formulation, Flortec, in patients with irritable bowel syndrome: a multicenter, randomized … doi:10.1097/MCG.0b013e31817fadd6 PubMed
  67. [67] S Macfarlane et al.. Aliment Pharmacol Ther. 2006. Review article: prebiotics in the gastrointestinal tract. doi:10.1111/j.1365-2036.2006.03042.x PubMed
  68. [68] W Scheppach et al.. Br J Nutr. 2001. Beneficial health effects of low-digestible carbohydrate consumption. doi:10.1079/bjn2000259 PubMed
  69. [69] M Olesen et al.. Am J Clin Nutr. 2000. Efficacy, safety, and tolerability of fructooligosaccharides in the treatment of irritable bowel syndrome. doi:10.1093/ajcn/72.6.1570 PubMed

Avertissement FDA: Ces déclarations n'ont pas été évaluées par la Food and Drug Administration. Les produits et informations sur ce site ne sont pas destinés à diagnostiquer, traiter, guérir ou prévenir quelque maladie que ce soit. Les notes de preuve présentées sont basées sur notre analyse de la recherche publiée et évaluée par des pairs et ne constituent pas un avis médical. Consultez toujours votre professionnel de santé avant de commencer tout régime de compléments alimentaires.